3190.3000 -22.80 (-0.71%)
NSE Aug 08, 2025 15:31 PM
Volume: 60,273
 

3190.30
-0.71%
Karvy
Strong growth and margin expansion in Q2FY17 on YoY basis: The company has grown into a national level lab with a hub-and-spoke model, that handled 15.5 Mn samples in H1FY17. On an average 7.04 Mn patients are depending on DLPL for the trusted accurate results. Post monsoon period,seasonal vector bound fevers like malaria, dengue, chikungunya contributed 2% to the volume growth and 3% to the revenue during the quarter. DLPL posted agood revenue growth of 21.5% YoY to Rs.2622 Mn in Q2FY17.
Number of FII/FPI investors decreased from 382 to 358 in Jun 2025 qtr
More from Dr. Lal Pathlabs Ltd.
Recommended